Mar. 26 2024
Source Page: Whole of Government Accounts, 2021-22Found: Business Interruption Loan Scheme (CBILS) 26.4 109,877 Coronavirus Large Business Interruption
Report Mar. 26 2024
Committee: Women and Equalities CommitteeFound: Vaccination 58.
Asked by: Baroness Hollins (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made, if any, in reaching a settlement in cases of individuals who have developed (1) blood clots, and (2) life-changing conditions, such as transverse myelitis, after receiving the COVID-19 AstraZeneca vaccine; and what assessment they have made of the level of payment being awarded under the Vaccine Damage Payment scheme.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government knows there are some extremely rare cases where individuals have sadly experienced harm following vaccination against COVID-19, and recognises how difficult this is for those individuals and their families. It would not be appropriate to comment on individual cases, including where there may be ongoing litigation that may involve the Government.
As part of business-as-usual work, the Government reviews the payment amount of the Vaccine Damage Payment Scheme (VDPS), alongside all routine policy on a regular basis. There are no plans at this time to change the level of payment awarded under the VDPS.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans she has to roll out the Covid 19 vaccination programme.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government remains committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). On 7 February 2024, the JCVI published further advice on the United Kingdom’s COVID-19 vaccination programme. The JCVI advice is that a COVID-19 vaccine should be offered in spring 2024 to those at greatest risk of serious disease, and who are therefore most likely to benefit from vaccination. Those eligible are:
- adults aged 75 years old and over;
- residents in a care home for older adults; and
- individuals aged six months old and over who are immunosuppressed, as defined in chapter 14a of the Green Book.
The Government has accepted this advice, with the spring 2024 COVID-19 vaccination programme planned to start in the middle of April. The JCVI will continue to review the optimal timing and frequency of future COVID-19 vaccination beyond spring 2024, and will provide further advice in due course.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 29 May 2023Found: Furthermore, different batches would have been used at different stages of the vaccination campaign,
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: COVID -19 Coronavirus Disease 2019 .
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: 1 0 Vaccination site haematoma 1 0 Vaccination site hypertrichosis 1 0 Vaccination
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: 40 0 Tenderness 2 0 Therapeutic and nontherapeutic responses Drug ineffective 1 0 Vaccination
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: discomfort NEC Axillary pain 5 0 Chest discomfort 2 0 Chest pain 4 0 Pain 5 0 Vaccination
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: discomfort 2 0 Chest pain 11 0 Facial pain 1 0 Pain 13 0 Tenderness 1 0 Vaccination